Perceived Deficits Questionnaire to capture decline in cognitive function. Participants report the extent to which they have experienced those symptoms or problems during the past week. Each of the symptoms or problems is indicated with four extents, including " never" for 0 score, "rarely" for 1 score, " sometimes" for 2 score and " often" for 3 score, "almost always"for 4 score. A higher score indicated a more serious decline in cognitive function.

Patient Health Questionnaire to measure the severity of depression. Participants report the extent to which they have experienced those symptoms or problems during the past week. Each of the symptoms or problems is indicated with four extents, including "not at all" for 0 score," several days " for 1 score, " more than half the days " for 2 score and " nearly every day " for 3 score. A higher score indicated a worse state.

GAD-7 (Generalized Anxiety Disorder-7) questionnaire to evaluate anxiety: includes scores for all 7 items and date of self-assessment at T0 to T3.

Participants report the extent to which they have experienced those symptoms or problems during the past week. Each of the symptoms or problems is indicated with four extents, including "not at all" for 0 score," several days " for 1 score, " more than h

ISI (Insomnia Severity Index) questionnaire to evaluate Insomnia Severity: includes scores for all 7 items and date of self-assessment .

Participants report the extent to which they have experienced those symptoms or problems during the past two weeks. Each of the symptoms or problems is indicated with four extents, the total value range from 0 to 21, and higher scores mean a more severe insomnia.

Therapy Administration Satisfaction Questionnaire is a 12-item questionnaire measuring the impact of each mode of treatment administration on five domains: physical impact, psychological impact, impact on activities of daily living, convenience, and satisfaction. Each of the domain/scale scores is scored on a 1-100 scale, where 0 is worst and 100 is best.

Clinical characteristics: include pathological TNM stage, histological grade, ER/PR status, HER2 Status, Ki-67 index, pathological subtype, WHO Performance Status score at T0, and menopausal status.

TNM stage will be recorded according to the pathology results, histological grade will be documented by WHO grade I to III, ER/PR status will be measured with immumohistochemical staining.

WHO Performance Status score will be classified into 0-4 levels. 0: able to carry out all normal activity without restriction.

1. restricted in strenuous activity but ambulatory and able to carry out light work.
2. ambulatory and capable of all self-care but unable to carry out any work activities; up and about more than 50% of waking hours.
3. symptomatic and in a chair or in bed for greater than 50% of the day but not bedridden.
4. completely disabled; cannot carry out any self-care; totally confined to bed or chair.

Patients receiving neoadjuvant or adjuvant treatments in fact.

Clinical treatment: include breast surgery (Mastectomy vs. Conservative surgery), axillary surgery (axillary dissection vs sentinel node biopsy), radiotherapy, anti-HER2 antibody therapy (pertuzumab vs. trastuzumab), anti-HER2 TKI therapy (yes vs. no), chemotherapy (yes vs. no).